WSC 2023 | Transitioning from alteplase to tenecteplase for stroke thrombolysis in the UK

Keith Muir, MD, PhD, Queen Elizabeth University Hospital, Glasgow, UK, anticipates a shift in the standard of care for stroke thrombolysis from alteplase to tenecteplase in the coming years. This is supported by evidence from multiple randomized, controlled trials confirming the non-inferiority of tenecteplase. This is sufficient to drive the shift due to its ease of administration: tenecteplase requires a single bolus injection whereas alteplase requires longer duration intravenous infusion. The main barrier to this transition is the current capacity of drug manufacturing. There is a need for improved production of large quantities of tenecteplase at the appropriate dosage for stroke thrombolysis to enable this transition. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.